Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01158170 : Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)
PhasePhase 3
AgesMin: 18 Years Max: 75 Years
Inclusion Criteria:

1. Patients were required to have histologically or cytologically documented

2. NSCLC and no brain metastasis documented by magnetic resonance imaging (MRI)within 21
days after confirmed response (RR+SD) to chemotherapy

3. No previous history of radiotherapy and surgery of brain

4. good response( CR/PR) to Erlotinib or Gefitinib.

5. Agree to radiotherapy

6. age > 18 and <75 years,ECOG performance status 1 or less

7. Good renal and hepatic and haematological (absolute neutrophils count 15 x1O9/L and
platelet count 90 x 109/L,HB>=80g /DL) functions

8. Have provided informed consent

Exclusion Criteria:

1. Seizure cannot be controled by the drugs

2. Combined with other disease of the brain such as tumour or infarction

3. Hypersensitivity to MR enhancer -
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557